• Natera (NasdaqGS:NTRA) and Incyte announced a clinical collaboration using Signatera in a Phase II colorectal cancer immunotherapy trial.
• The study will use Signatera minimal residual disease testing as both a primary and secondary endpoint to assess treatment impact.
• Signatera results are also planned to guide trial enrollment, placing the assay at the center of patient selection in the study.
• This new Natera and Incyte Phase II immunotherapy collaboration builds on a wider pattern our research has been tracking. Take a look at 1 warning sign we have identified for Natera.

For readers watching how cancer diagnostics and treatment are converging, the wider trend in oncology-focused healthcare AI is worth a look at 35 healthcare AI stocks.

Natera focuses on molecular testing services, so this colorectal cancer trial plugs directly into its broader push to apply personalized diagnostics to real-world treatment decisions in oncology.

Does the team leading Natera have what it takes? See our full breakdown of the management team's track record and compensation.

How does this Incyte deal fit Natera’s bigger oncology push?

The Incyte trial puts Signatera not just in the lab, but inside treatment decision making as a primary and secondary endpoint. That supports the broader idea that Natera’s MRD technology can move from being a test ordered by doctors to a gatekeeper for who receives therapies in high value cancer settings.

What does the collaboration say about leadership continuity after the CEO switch?

New CEO Solomon Moshkevich has been closely tied to Signatera, oncology expansion and clinical trial work since 2011. A fresh Phase II partnership that leans on Natera’s MRD design expertise suggests that the leadership change is keeping the same oncology priorities rather than resetting the playbook.

What single development would really test whether this deal matters for Natera?

The clearest check will be whether this Phase II study leads to an expanded partnership or a larger Phase III program that still relies on Signatera for patient selection and endpoints. A follow-on agreement with Incyte, announced after the Phase II readout, would be the concrete signal to watch next.

Add Natera to your Watchlist and get alerts as these catalysts play out.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.